Findings

What do systematic reviews say?

191 questions · 225 findings · 21 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 50 · 22.2%GRADE not reported 8 · 3.6%Very low 62 · 27.6%Low 55 · 24.4%Moderate 38 · 16.9%High 12 · 5.3%

Corticosteroids vs placebo

Diarrhoea (grade 2+) · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Corticosteroids vs placebo

QoL · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sucralfate vs placebo

Mean GI symptom scores · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sucralfate vs placebo

Acute and late GI toxicity (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

Summary of findings: Sucralfate showed no clear difference in acute and late GI toxicity (grade 2+) [acute = during RT; late = 6… compared with placebo (moderate certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 1.07 [0.83, 1.39]
1 study · 335 participants
Moderate

Sucralfate vs placebo

Diarrhoea (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

Summary of findings: Sucralfate may leads to lower diarrhoea (grade 2+) [during RT] compared with placebo (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.81
4 studies · 284 participants
Low

Sucralfate vs placebo

QoL · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Sodium butyrate vs placebo

Mean GI symptom scores · Men undergoing RT for prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Sodium butyrate vs placebo

Acute and late GI toxicity (grade 2+) · Men undergoing RT for prostate cancer

Summary of findings: Sodium butyrate showed no clear difference in acute and late GI toxicity (grade 2+) compared with placebo (moderate certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.91 [0.41, 1.98]
1 study · 79 participants
Moderate

Summary of findings: Sodium butyrate vs placebo

Diarrhoea (grade 2+) · Men undergoing RT for prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Sodium butyrate vs placebo

QoL · Men undergoing RT for prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Misoprostol vs placebo

Outcomes1 · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Misoprostol vs placebo

Mean GI symptom scores · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Misoprostol vs placebo

Acute and late GI toxicity (grade 2+) · Men with prostate cancer

Summary of findings: Misoprostol showed no clear difference in acute and late GI toxicity (grade 2+) compared with placebo (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 1.38 [0.76, 2.51]
1 study · 100 participants
Low

Misoprostol vs placebo

Diarrhoea (grade 2+) · Men with prostate cancer

It is very uncertain whether summary of findings: Misoprostol changes diarrhoea (grade 2+) compared with placebo (very low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 1 [0.46, 2.19]
1 study · 100 participants
Very low

Misoprostol vs placebo

QoL · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Magnesium oxide vs placebo

Mean GI symptom scores (during RT) · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Magnesium oxide vs placebo

Acute and late GI toxicity (grade 2+) · Men with prostate cancer

Summary of findings: Magnesium oxide showed no clear difference in acute and late GI toxicity (grade 2+) compared with placebo (moderate certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 1.7 [0.87, 3.31]
1 study · 92 participants
Moderate

Summary of findings: Magnesium oxide vs placebo

Diarrhoea (grade 2+) · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Magnesium oxide vs placebo

QoL · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Octreotide vs placebo

Outcomes1 · People undergoing RT for pelvic cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found